Tofacitinib Seen as Effective and Safe for AAV Patients in Pilot Study

Tofacitinib Seen as Effective and Safe for AAV Patients in Pilot Study

306039

Tofacitinib Seen as Effective and Safe for AAV Patients in Pilot Study

Treatment with tofacitinib is well tolerated and effectively induces remission in people with ANCA-associated vasculitis (AAV), while enabling patients to lower their glucocorticoid doses, a small pilot study suggests. These results indicate that tofacitinib may represent a treatment option for active AAV. However, a larger and randomized controlled trial is needed to confirm the therapy’s efficacy and safety in this patient group, the researchers wrote. “Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study,”…

You must be logged in to read/download the full post.